Radiology 2021 02 1;298(2):296-305. Epub 2020 Dec 1.
From the Department of Diagnostic Radiology, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510 (M.A.D.); Advocate Lutheran General Hospital, Park Ridge, Ill (S.M.F., F.M.D.); Department of Radiology, University Hospitals of Cleveland Medical Center, Cleveland, Ohio (D.M.P.); Albert Einstein Healthcare Network, Philadelphia, Pa (D.S.C.); Invision Sally Jobe Breast Centers and Radiology Imaging Associates, Denver, Colo (L.D.B.); TOPS Comprehensive Breast Center, Houston, Tex (S.L.R.); Solis Women's Health, Dallas, Tex (S.L.R.); Radiology Associates of Hollywood and Memorial Healthcare System, Hollywood, Fla (M.K.H.); John C. Lincoln Breast Health and Research Center, Phoenix, Ariz (L.N.G.); and Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pa (E.F.C.).
Background Screening with digital breast tomosynthesis (DBT) improves breast cancer detection and recall rates compared with those obtained with digital mammography (DM); however, the impact of DBT on patient survival has not been established. False-negative (FN) screening examinations can be a surrogate for long-term outcomes, such as breast cancer morbidity and mortality. Purpose To determine if screening with DBT is associated with lower FN rates, detection of cancers with more favorable prognoses, and improved performance outcomes versus DM. Read More